Loading...
Loading...
Oculus Innovative
Sciences, Inc.
OCLS a healthcare company that designs, produces and
markets innovative, safe and effective anti-infective products and medical
devices while also developing multiple drug candidates, today announced the
issuance of new U.S. patent for the use of Microcyn® Technology in the
treatment of skin ulcers. In this application, Microcyn Technology can be
delivered to skin ulcers via washing, irrigation and soaking or through
application of a wound dressing saturated in the Microcyn Technology.
According to claims allowed by the patent examiner, the application of the
Microcyn Technology via these methods will:
* Reduce the microbial load of an infected diabetic foot ulcer;
* Decrease the recurrence rate of an infected diabetic foot ulcer;
* Decrease the likelihood of dehiscence of an infected diabetic foot ulcer;
* Decrease the likelihood of amputation resulting from an infected diabetic
foot ulcer;
* Decrease the likelihood of systemic inflammatory response syndrome from an
infected diabetic foot ulcer;
* Decrease the likelihood of sepsis resulting from
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Posted In: News
We simplify the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in